IGFBP-3 enhances irinotecan efficacy in colorectal cancer via ROS-mediated apoptosis and β-catenin suppression Authors: Elahe Gharehkhani, Mohammad Karami, Abouzar Bagheri, Mahboube Rahmati Kukandeh, Mohammad Shokrzadeh Published: 2026 ABSTRACT Background and purpose:Colorectal cancer, a leading cause of mortality, is treated with surgery early and irinotecan (IRI) chemotherapy in advanced stages. Insulin-like growth factor-binding protein 3 (IGFBP-3), regulated by p53, mediates tumor suppression and apoptosis. This study evaluates the combined therapeutic effects of IGFBP-3 and IRI in colorectal cancer.Experimental approach:SW480 colorectal cancer cells were treated with IGFBP-3, IRI, and their combination; IC50 values were determined by MTT assay, and combination effects were analyzed by CompuSyn. Oxidative stress markers, apoptosis, and cell cycle progression were assessed utilizing flow cytometry. Furthermore, caspase 3/7 activity was measured, and expression levels of Bax, Bcl2, and β-catenin were determined using RT-PCR.Findings/Results:The MTT assay revealed IC50 of 8.4 μM for IRI and 43.03 nM for IGFBP-3, with CompuSyn confirming synergistic interaction (CI < 1). Compared to single agents, the combination treatment significantly enhanced apoptosis, induced greater G2/M cell cycle arrest, and markedly increased levels of ROS, MDA, and protein carbonyls while significantly depleting GSH. At the molecular level, the combination synergistically upregulated pro-apoptotic Bax and downregulated anti-apoptotic Bcl2 and oncogenic β-catenin.Conclusion and implications:Our results indicated that IRI and IGFBP-3 show cytotoxicity, with IGFBP-3 enhancing IRI effect by inhibiting Wnt/β-catenin and increasing drug uptake, warranting assessment in normal cells. INTRODUCTION Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide, with more than 1.85 million new cases and 850,000 deaths each year. It results from complex genetic and signaling pathway changes(1). Inherited mutations in the adenomatous polyposis coli (APC) gene, DNA repair genes, K-ras, or p53 lead to uncontrolled cell growth, which causes colorectal cancer development and progression(2). Surgery is the primary treatment for CRC stages 0-II; advanced stages require adjuvant chemotherapy, targeted therapy, or combination therapies(34). Chemotherapy and radiotherapy can be used pre- or post-surgery to reduce or control tumors. Modern chemotherapy includes single agents, such as 5-fluorouracil (5-FU), oxaliplatin (OX), irinotecan (IRI), and capecitabine (CAP or XELOX), as well as combination regimens like FOLFOX, FOLFIRI, XELOX, and CAPIRI. Single-agent therapy is suitable for patients with a lower risk or poor health; efficacy is similar across regimens, differing mainly in their toxicity profiles(56). In the United States, IRI is approved for first-line treatment of metastatic CRC, either alone or combined with 5-FU and leucovorin(7). Chemically, it is a camptothecin derivative and acts as a prodrug that is metabolized into its active form, SN-38(8). IRI and SN-38 inhibit topoisomerase I by stabilizing the Topo I-DNA complex, forming a ternary inhibitory complex(9). This interaction results in the reversible cleavage of single-stranded DNA, ultimately disrupting DNA replication and transcription processes(10). Resistance mechanisms to IRI have been extensively studied, with a primary focus on pharmacokinetic factors. Variability in individual drug response arises from differences in metabolism, carboxylesterase activity, cellular uptake, and the function of ATP-dependent efflux transporters(11). IRI-based therapies improve survival but frequently cause intestinal mucositis, a common and severe adverse effect of anticancer treatments(12). Intestinal mucositis causes severe gastrointestinal mucosal damage, leading to symptoms and increased risk of infection. Therefore, strategies are needed to minimize toxicity without compromising the efficacy of cancer treatment(13). Insulin-like growth factor binding protein 3 (IGFBP3) is a key member of the IGF binding protein family(14). IGFBP3, beyond stabilizing IGFs in blood, modulates IGF-1 receptor signaling, thereby influencing cellular growth and survival pathways(15). In the context of CRC, IGFBP-3 is of particular interest because its expression has been linked to better patient prognosis. It is also known to inhibit key oncogenic pathways, such as protein kinase B (Akt) and Wnt/β-catenin, which are frequently dysregulated in this malignancy(16). IGFBP3 inhibits IGF1R signaling by sequestering IGFs, thereby regulating cellular growth, metabolism, and related downstream pathways(17). This dual role highlights the importance of IGFBP-3 in maintaining the balance of IGF bioavailability and activity in both systemic and tissue-specific contexts(18). IGFBP3 expression is regulated by the p53 pathway, highlighting its crucial role in tumor suppression and growth regulation mechanisms(19). Although p53 influences IGFBP3 regulation, its expression is not exclusively p53-dependent; p53-independent mechanisms also contribute to modulating IGFBP3 levels(2021). IGFBP3, mainly produced in the liver, regulates cellular growth and apoptosis by binding to IGFs, thereby controlling their bioavailability and biological activity(22). This interaction not only contributes to growth inhibition but also plays a significant role in the induction of programmed cell death(2324). Studies show decreased IGFBP3 serum levels in lung cancer, whereas its expression promotes mammary cell proliferation, indicating cancer-type-specific roles for IGFBP3(2526). Furthermore, research has indicated that IGFBP3 expression is significantly reduced in patients with pancreatic cancer compared to healthy controls(27). Given the varying roles of IGFBP3 in different cancers, the therapeutic potential of IGFBP3, the side effects of IRI, and the lack of research on their combined use in colon cancer, we aimed to investigate the effects of co-administering these two agents. MATERIALS AND METHOD Chemicals Fetal bovine serum (FBS), penicillin/streptomycin, Dulbecco’s modified Eagle medium with high glucose (DMEM H.G.), and phosphate-buffered saline (PBS) were sourced from DenaZist (Iran). Trypan blue and trypsin-EDTA were obtained from KalaZist (Iran). Recombinant human IGFBP3 (100-08-25Ug; Germany) was purchased from Peprotech. IRI (Rinteca 100) was supplied by aCtERO (Iran). Additionally, the cDNA (complementary DNA) synthesis kit (A101161) and the total RNA extraction kit were acquired from Parstous (Iran). The fluoresceinisothiocyanate (FITC)-annexin V apoptosis detection kit (MBR-001, A-002, A-003) was procured from Mahboub BioResearch (Iran). RNase A (5438) was obtained from Kiagene (Iran), and the caspase 3/7 activity assay kit (KCAS37; Iran) was purchased from Kalazist (Iran). Cell culture and compounds The human colorectal cancer cell line SW480 (C506) was obtained from the Pasteur Institute (Tehran, Iran). The cells were maintained as a monolayer culture in T-25 flasks using high-glucose DMEM, supplemented with high glucose, L-glutamine, 10% FBS, and 1% penicillin/streptomycin (containing 5000 U/mL penicillin and 5000 μg/mL streptomycin). The cells were incubated at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Subculturing and harvesting were performed when the cells reached approximately 90% confluence (Fig. 1). SW480 cells at 90% confluence, magnification of 40×. Antiproliferative in vitro assay SW480 cells were seeded at a density of 1 × 104 cells per well in 96-well plates and allowed to adhere overnight. The cells were then treated with varying concentrations of IGFBP3 (8.75, 17.5, 35, 70, and 140 nM)(2829) and IRI (1.875, 3.75, 7.5, 15, and 30 μM)(3031), both as single agents and in combination. After a 48-h incubation period at 37 °C under standard culture conditions, cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Absorbance measurements were taken at a wavelength of 540 nm. The growth of cells treated with the test compounds was calculated as a percentage relative to the untreated control group(3233). For the combination studies, dose-effect relationships were analyzed using CompuSyn Software (Biosoft, Cambridge, UK) based on the median-effect principle established by Chou and Talalay. The combination index (CI) values were calculated to evaluate the interaction between the two drugs. A CI value of less than 1 indicates synergism, a CI equal to 1 represents additive effects, and a CI greater than 1 signifies antagonism. The mean CI values were derived to quantify the nature of the drug interactions(34). The concentrations for all subsequent experiments were selected based on the initial cytotoxicity and synergy analyses. For single-agent treatments, sub-IC50 were used: IRI at 3.75 μM (~45% of its IC50) and IGFBP-3 at 17.5 nM (~41% of its IC50). This allowed for the observation of enhanced effects in combination therapy without excessive single-agent toxicity. The specific combination concentration (IRI 3.42 μM + IGFBP-3 16.21 nM) was derived from the CompuSyn software analysis, which identified this ratio as highly synergistic (CI < 1) with a favorable dose-reduction index (DRI > 1) for both drugs, enabling effective cell death at reduced concentrations. The cytotoxicity of the treatments was calculated utilizing equation (1), and we used the blank as a reference to normalize the measurements. Assessment of oxidative stress In this analysis, we assessed oxidative stress markers in SW480 cells by measuring reactive oxygen species (ROS), malondialdehyde (MDA), protein carbonyl, and reduced glutathione (GSH) levels. The documents were guided using specific assays: ROS was detected with 20, 70-dichlorofluorescein diacetate (DCFH-DA), lipid peroxidation (MDA) was calculated via the thiobarbituric acid (TBA) method, protein oxidation was settled using 2,4-dinitrophenylhydrazine (DNPH), and GSH loaded was analyzed with 5,5ʹ-dithio-bis-(2-nitrobenzoic acid) (DTNB). Untreated cells were used as the negative control group. All test repeated five times. Measuring ROS levels within cells Intracellular ROS levels were assessed by the DCF assay. In summary, SW480 cells (1 × 104 cell/well) were seeded in black 96-well plates overnight. Then, cells were incubated with IGFBP3 at 17.5 nM, IRI at 3.75 μM, and a combination of IGFBP3 (16.21 nM) and IRI (3.42 gM) for 48 h. Following this treatment period, the medium was removed. A fresh, serum-free medium containing 20 μM DCFH-DA was added to each well, and the cells were incubated at 37 °C for 30 min in the dark. Finally, the fluorescence intensity of DCF was calculated at 528 nm emission and 485 nm excitation using a Synergy H4 microplate reader (Synergy H1, Biotek, USA)(3536). Analysis of MDA Lipid peroxidation is defined by the spectrophotometric method based on the reaction between MDA and TBA. MDA, an indication for lipid peroxidation, was evaluated by using (TBA) quantified by dissolving 158 mg of TBA in 10 mL of distilled water. The mixture was heated at 95 °C for 60 min, then chilled to room temperature and centrifuged at 12,000 rpm for 10 min to eliminate interfering substances. The absorbance was measured at 545 nm using a UV-Vis spectrophotometer(37). The MDA content was determined via the following equation: Protein carbonyl detection Protein carbonyl groups are an important and immediate biomarker of oxidative stress. DNPH tagging of protein carbonyls has been one of the most common measures of oxidative stress. DNP hydrazones formed from the reaction (the derivatization of the CO group with DNPH) are easily quantifiable at 375 nm. Briefly, 1 × 106 SW480 cells/well were seeded in a 24-well plate supplemented with DMEM H.G. The plate was then placed in an incubator at 37 °C for 24 h with 5% CO2 and 95% humidity. All treatments included 0.1% dimethyl sulfoxide (DMSO) vehicle controls. After the incubation period, 50 μL of various concentrations of DMSO (0.1% v/v)-sonicated compounds were added to the 96-well plate and incubated for 48 h, and the medium was changed daily. Wells without DMSO, IRI, and IGFBP3 served as a negative control, and wells with 10 μL of hydrogen peroxide (H2O2; final concentration was 800 μM) were considered the positive control. The cells were harvested and transferred to microtubes, then washed with 1 mL of PBS. Then, cells were homogenized using mechanical cell disruption in 500 μL water only (without any buffer or components). The samples were centrifuged at 10,000 g for 10 min to spin down any insoluble materials. The total protein of each sample was measured as mentioned above. As nucleic acids interfere with the assay, the 280/260 nm ratio was checked to make sure it is greater than 1. Then, 100 μL of DNPH (4.08 mg DNPH in 2 mL Hydrochloric acid (HCL) 2M) was added to 250 μL of the samples, vortex and incubated for 10 min at room temperature. Then, 30 μL of trichloroacetic acid (TCA) solution 20% v/v was added to each sample, vortexed, and placed on ice for 5 min, spun at maximum speed for 2 min, and then the supernatant was discarded without disturbing the pellet. Subsequently, 500 μL of cold acetone was added to each tube, and the pellet was washed to remove free DNPH. To effectively disperse the pellets, 30 s bath sonication was carried out, following placing at -20 °C for 5 min and centrifuging for 2 min, and carefully removing acetone. of Guanidine solution (200 μL, 6 M) was added and sonicated briefly. Most proteins will be resolubilized easily at this point. For those proteins that are resistant to re-solubilization, sonication for a few seconds, then letting the solution sit at 60 °C for 15-30 min is recommended. Spin very briefly to pellet any insolubilized material and transfer 100 μL of each sample to the 96-well plate. Optical density (ODs) at ~375 nm was measured in a hybrid reader (Synergy H1, Biotek, USA). The carbonyl content was determined as follows(38): 6.364 is the extinction coefficient using the enclosed 96-well plate in mM (= 22 mM-1 cm-1 × 0.2893 cm path length in well). Measuring GSH The assay is based on the GSH recycling system by DTNB and GSH reductase. DTNB and GSH react to generate 2-nitro-5-thiobenzoic acid, which has a yellow color. Therefore, GSH concentration can be determined by measuring absorbance at 412 nm. Shortly, the 1 × 106 SW480 cells/well were seeded in a 6-well plate supplemented with DMEM H.G. The plate was then placed in an incubator at 37 °C for 24 h with 5% CO2 and 95% humidity. After the incubation period, 200 μL of various concentrations of DMSO (0.1% v/v)-sonicated compounds were added to the 6-well plate and incubated for 48 h. Cells that received no treatment (IRI or IGFBP3) were used as the negative control. The cells were transferred to microtubes, then washed with 1 mL of cold PBS. To measure the protein content, 106 cells were centrifuged, then the cell pellet was lysed and homogenized by dissolving in 1 mL of EDTA 25.5 mM. Then, 0.5 mL of EDTA 25.5 mM and 1.5 mL of TCA 10% w/v were added to microtubes. Samples were centrifuged at 3500 g for 10 min to remove protein (deproteination) and insoluble materials. Then, 120 μL of tris aminomethane 400 mM was added into 120 μL of the samples’ supernatant, and standards (0, 25, 50, 75, 100, and 200 μM). Finally, 200 μL of the sample/tris aminomethane mixture and 100 μL of Elman reagent (24.5 mg of DTNB in 25 mL of sodium acetate 100 mM) were added to a 96-well microplate and allowed to incubate at room temperature for 5 min. The spectrophotometer was set to zero using a blank cuvette filled with a zero standard. The color intensity of the wells’ content was measured using a microplate reader (ChroMate, Awareness, USA) at an OD of 405 nm. GSH content was determined as follows: Apoptosis assay To assess cellular apoptosis, a dual-staining approach was utilized with a FITC-conjugated annexin V and propidium iodide (PI) apoptosis detection kit, obtained from Mahboub Bio Research (Iran). This method allows for the differentiation of apoptotic and necrotic cell populations based on the binding of annexin V to phosphatidylserine, exposed on the cell membrane, and the exclusion or uptake of PI, respectively(39). SW480 cells were plated in 6-cm culture di shes and treated with IRI, IGFBP3, or their combination for 48 h, after which cellular analysis was performed. For the control groups, triplicate sets of untreated cells were prepared without staining. One set of control cells was exposed to 3% H2O2 for 30 s and subsequently stained with PI without FITC. Another set was treated with 3% H2O2 for 4 h and stained with FITC without PI to serve as additional controls. Following treatment, cells were trypsinized, harvested, and washed twice with cold PBS. The cell concentration was adjusted to 1 × 106 cells/mL, and the suspension was prepared in 1× binding buffer. Aliquots of 100 μL were transferred to 5 mL polystyrene tubes and co-stained with PI and annexin V-FITC. The tubes were incubated for 15 min at room temperature in the absence of light. Finally, 400 μL of 1× binding buffer was added to each tube, and the apoptotic cell population was quantified using flow cytometry(40). Cell cycle assessment Following the specified treatments, cells were plated in 6-cm culture dishes and treated with the test compounds. Subsequently, the cells were fixed using ice-cold 70% ethanol, washed twice with PBS, and resuspended in a solution containing PI (10 mg/mL) and ribonuclease A (0.1%) in PBS for 30 min. The cells were then incubated in the dark at room temperature for an additional 30 min. DNA content was analyzed using a Partec PAS flow cytometer equipped with a 488 nm argon laser. All experiments and analyses were conducted in triplicate to ensure reproducibility and reliability(41). Caspase activity analysis The SW480 cells were exposed to IRI and IGFBP3, and each treatment condition was tested in triplicate (three replicates per group). Caspase 3 activity was measured using CellEvent caspase-3/7, an assessment of apoptosis by Green Flow Cytometry Assay. The cell suspensions were centrifuged at 100 g for 7 min at 37 °C to pellet the cells. After centrifugation, the supernatants were aspirated, and the cell pellets were resuspended in 500 μL of PBS. Next, 0.5 μL of the CellEvent caspase 3/7 green detection reagent was added to each sample to assess apoptotic activity. The cells were then incubated at 37 °C for 30 min to allow caspase-dependent fluorophore activation. Following incubation, the samples were analyzed using a BD FACSCalibur flow cytometer to quantify caspase 3/7-positive cells(42). The caspase 3/7 activity was determined as follows: Reverse transcriptase-polymerase chain reaction analysis Total RNA was extracted from both treated and untreated SW480 cells using the PARSTOUS kit, following the manufacturer’s protocol. The concentration and purity of the RNA were assessed spectrophotometrically using a NanoDrop instrument (Epoch Microplate Spectrophotometer, USA). All RNA samples exhibited an A260/A280 absorbance ratio exceeding 1.8, indicating high purity. For cDNA synthesis, 1 μg of total RNA was initially heat-denatured at 65 °C for 5 min. Reverse transcription reactions (20 μL) were then performed under the following conditions: 10 min at 25 °C, 50 min at 42 °C, and a final incubation at 80 °C for 5 min. The resulting cDNA was diluted fivefold before being used for quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). For the synthesis of cDNA corresponding to microRNAs (miRs), a reaction mixture containing a pool of stem-loop primers specific to each target miR was prepared. First-strand cDNA synthesis was conducted using ProtoScript II reverse transcriptase. Following an initial heat denaturation step (65 °C for 5 min), the reactions (10 μL) were incubated at 16 °C for 30 min, followed by 42 °C for 30 min, and a final step at 80 °C for 5 min. The cDNA generated from miRs was diluted 50-fold before qRT-PCR analysis. All cDNA samples were stored at -20 °C until further use in qRT-PCR experiments(43). The expression of Bcl2, Bcl2-associated X (Bax), and β-catenin relative to GAPDH was determined using 2-ΔΔCt, where ΔΔCt equals ΔCt (T) - ΔCt (C), in which T refers to the treatment groups and C to the control. The sequences of the primers used in this study are provided in Table 1. Table 1Primers used for genes Bax, BCL2, β-catenin, and GAPDH.GenesPrimers’ sequences Bax Forward: 5ʹ-CCAAGAAGCTGAGCGAGTGT-3ʹ; Reverse: 5ʹ-TGTCCAGCCCATGATGGTTC-3ʹ BCL2 Forward: 5ʹ-CTGTGGATGACTGAGTACCTGA-3ʹ; Reverse: 5ʹ-AGCCAGGAGAAATCAAACAGAGG-3ʹ β-catenin Forward: 5ʹ-GATACCTCCCAAGTCCTGTATGAG-3ʹ; Reverse: 5ʹ-GCATCAAACTGTGTAGATGGGATC-3ʹ GAPDH Forward: 5ʹ-CCCCCAATGTATCCGTTGTG-3ʹ; Reverse: 5ʹ-TAGCCCAGGATGCCCTTTAGT-3ʹ Primers used for genes Bax, BCL2, β-catenin, and GAPDH. Statistical analysis The data analysis was conducted using a one-way ANOVA followed by Tukey’s multiple comparison test. All data were processed using GraphPad Prism (Version 8) statistical software. The results are presented as mean ± SD. P-values < 0.05 were considered statistically significant. RESULTS Cells confluency Cells were subjected to the specified assays once they reached approximately 90% confluence for each experimental condition (Fig. 1). IGFBP-3 cytotoxicity on the SW480 cells The IGFBP3 concentration range was selected based on earlier studies. The MTT assay demonstrated that concentrations of 17.5, 35, 70, and 140 nM inhibited the growth of SW480 cells. The IC50, calculated using GraphPad Prism (version 8), was 43.03 ± 3.52 nM (Fig. 2). (A) The cytotoxic effect of IGFBP3 on the SW480 cell line; (B) microscopic image of SW480 cells treated with IGFBP3 at 8.75, 17.5, 35, 70, and 140 nM (magnification: 400×). Data are presented as mean ± SD, n = 3. ***P < 0.001 indicates significant differences in comparison with the control group. IGFBP3, Insulin-like growth factor binding protein 3. IRI cytotoxicity on the SW480 cells The concentration range for IRI was selected based on previous studies. Cytotoxicity was assessed using the MTT assay, which revealed concentration-dependent effects at 1.875, 3.75, 7.5, 15, and 30 μM. The IC50 of IRI was determined to be 8.4 ± 0.53 μM (Fig. 3). (A) The cytotoxic effect of IRI on the SW480 cell line; (B) microscopic image of SW480 cells treated with IRI at 1.875, 375, 7.5, 15, and 30 μM (magnification 400×). Data are presented as mean ± SD, n = 3. ***P < 0.001 indicates significant differences in comparison with the control group. IRI, irinotecan. Calculation of the synergistic concentration of IRI and IGFBP3 on the SW480 cells Chou-Talalay analysis using CompuSyn software demonstrated that the combination of IRI at 7.5 μM and IGFBP3 at 35 nM exerts synergistic effects on SW480 cells (Fig. 4 and Tables 2 and 3). (A) The cytotoxic effect of IRI and IGFBP3 combination on the SW480 cell line; (B) microscopic image of SW480 cells treated with IRI at 1.875, 375, 7.5, 15 and 30 μM and IGFBP3 at 8.75, 17.5, 35, 70 and 140 nM (magnification: 400×). Data are presented as mean ± SD, n = 3. ***P < 0.001 indicates significant differences in comparison with the control group. IRI, irinotecan; IGFBP3, Insulin-like growth factor binding protein 3. Table 2CompuSyn analysis of IRI, IGFBP3, and their combination.IRIIGFBP3The combination Concentration (μM) Effect Concentration (nM) IRI (μM) IGFBP3 (nM) Effect 1.8750.018.751.8758.750.111.8750.018.751.8758.750.151.8750.018.751.8758.750.133.750.0917.53.7517.50.623.750.1117.53.7517.50.653.750.1317.53.7517.50.617.50.3935.07.535.00.917.50.4135.07.535.00.957.50.4535.07.535.00.9115.00.9170.015.070.00.9915.00.9270.015.070.00.9915.00.9170.015.070.00.9930.00.98140.030.0140.00.9930.00.99140.030.0140.00.9930.00.97140.030.0140.00.99 15 Data points entered.15 Data points entered.15 Data points entered.X-int: 0.89427X-int: 1.56336Y-int: -2.7898 ± 0.08729Y-int: -4.9548 ± 0.17166m: 3.11967 ± 0.08970m: 3.16930 ± 0.10717Dm: 7.83921Dm: 36.5902r: 0.99467r: 0.99265IRI, Irinotecan; IGFBP3, Insulin-like growth factor binding protein 3. CompuSyn analysis of IRI, IGFBP3, and their combination. IRI, Irinotecan; IGFBP3, Insulin-like growth factor binding protein 3. Table 3Chosen concentration based on synergistic effects and DRI that is less than IC50.CI Data for non-constant combo: IRI + IGFBP3DRI Data for non-constant combo: IRI + IGFBP3 IRI (μM)IGFBP3 (nM)EffectCIIRI (μM)IGFBP3 (nM)DRI for IRIDRI for IGFBP3 1.875 8.750.110.930034.0106718.91762.139022.16202 1.875 8.750.150.830444.4956821.16752.397702.41914 1.875 8.750.130.875564.2622320.08512.273192.29544 3.75 17.50.620.818719.1711442.70202.445642.4412 3.75 17.50.650.785689.5598244.48292.549292.54188 3.75 17.50.610.829789.0478142.13672.412752.40781 7.5 35.00.910.9166816.457275.92872.194302.16939 7.5 35.00.950.7500620.145292.65022.686032.64715 7.5 35.00.910.9166816.457275.92872.194302.16939 15.0 70.00.990.8874634.1953155.9702.279692.22815 15.0 70.00.990.8874634.1953155.9702.279692.22815 15.0 70.00.990.8874634.1953155.9702.279692.22815 30.0 140.00.991.7749234.1953155.9701.139841.11407 30.0 140.00.991.7749234.1953155.9701.139841.11407 30.0 140.00.991.7749234.1953155.9701.139841.11407The yellow-highlighted cells indicate the best concentrations for combination therapy. IRI, irinotecan; IGFBP3, Insulin-like growth factor binding protein 3; CI, combination index; DRI, dose-reduction index. Chosen concentration based on synergistic effects and DRI that is less than IC50. The yellow-highlighted cells indicate the best concentrations for combination therapy. IRI, irinotecan; IGFBP3, Insulin-like growth factor binding protein 3; CI, combination index; DRI, dose-reduction index. The effect of the combination therapy on oxidative stress factors After exposing SW480 cells to IRI (3.75 μM), IGFBP3 (17.5 nM), and their combination, results showed that the combination therapy significantly increased oxidative stress factors, including ROS, MDA, and protein carbonyl, compared to the control group; on the other hand, it could decrease GSH intracellular level (Fig. 5A-D). The effects of IRI, IGFBP3, and their combination on (A) ROS, (B) MDA, (C) protein carbonyl, and (D) GSH levels in the SW480 cell line. Data are presented as mean ± SD, n = 3. **P < 0.01 and ***P < 0.001 indicate significant differences in comparison with the control group; ##P < 0.01, ###P < 0.001 versus IRI-treated cells. IRI, irinotecan; IGFBP3, insulin-like growth factor binding protein 3; ROS, reactive oxygen species; MDA, malondialdehyde; GSH, reduced glutathione. The effect of the combination therapy on apoptosis The combination of IRI and IGFBP-3 induced a total apoptosis rate (12.52%) which was comparable to or lower than that observed with IRI alone (15.75%) or IGFBP-3 alone (13.08%) (Fig. 6). Notably, although the combination did not increase apoptosis beyond single-agent levels, it induced a marked increase in necrosis (63.9% for the combination vs. 15.4% for IRI alone and 10.8% for IGFBP-3 alone), indicating that the enhanced cytotoxicity of the combination is largely driven by necrotic cell death. Annexin V-FITC/propidium iodide staining to measure apoptosis by flow cytometry. SW480 cells treated with IIR (3.75 μM), IGFBP3 (17.5 nM), and their combination. (A) Control; (B) combination; (C) IGFBP3; (D) IRI. Q1, necrosis; Q2, late apoptosis; Q3, early apoptosis; Q4, alive cells. IRI, irinotecan; IGFBP3, insulin-like growth factor binding protein 3. The effect of combination therapy on the SW480 cell cycle The results showed that IRI induced cell cycle arrest in the G2/M phase, while IGFBP3 caused arrest in the G0/G1 phase. The combination of both treatments increased arrest in both G0/G1 and G2/M phases, although to a lesser extent in G2/M compared to IRI alone (Fig. 7). Annexin V-FITC/propidium iodide staining to measure cell cycle by flow cytometry. SW480 cells treated with IRI (3.75 μM), IGFBP3 (17.5 nM), and their combination. (A) Control; (B) combination; (C) IGFBP3; (D) IRI-treated cells. IRI, irinotecan; IGFBP3, insulin-like growth factor binding protein 3. The effect of combination therapy on caspase 3/7 activity As illustrated in Fig. 8, although IRI (3.75 μM) raised caspase 3/7 activity in contrast to the control group, IGFBP3 (17.5 nM) had no significant variation. The combination therapy induced the most significant effect on caspase 3/7 activity compared to the control group, even in comparison with the IRI-treated cells. The effects of IRI, IGFBP3, and their combination on the activity of caspase 3/7 to determine cell apoptosis. Data are presented as mean ± SD, n = 3. ***P < 0.001 indicates significant differences in comparison with the control group; ###P < 0.001 versus IRI-treated cells. IRI, irinotecan; IGFBP3, insulin-like growth factor binding protein 3. The effect of combination therapy on the expression of Bax, Bcl-2, and β-catenin genes IRI treatment significantly decreased Bcl2 and β-catenin expression and increased Bax expression in contrast to the control group, while IGFBP3 had no significant effect on the expression of the genes of interest. qRT-PCR analysis demonstrated that the combination therapy caused a significantly greater reduction in Bcl2 and β-catenin mRNA levels, and a greater increase in Bax mRNA levels, than IRI treatment alone (Fig. 9A-C). On the other hand, the combination therapy showed stronger results than IRI. Bcl2, Bax, and β-catenin mRNA expression after treatment with IRI, IGFFBP3, and their combination. Data are presented as mean ± SD, n = 3. ***P < 0.001 indicates significant differences in comparison with the control group; #P < 0.05 and ##P < 0.01 versus IRI-treated cells. IRI, irinotecan; IGFBP3, insulin-like growth factor binding protein 3. DISCUSSION In this study, SW480 cells were treated with IRI and IGFBP3 individually and in combination. The IC50 of IRI was 8.4 ± 0.53 μM, and 43.03 ± 3.52 nM were obtained for IRI and IGFBP3, respectively. Using CompuSyn, the selected concentration for IRI and IGFBP3, in combination treatment, based on their DRI was 3.42 μM and 16.21 nM, respectively. Our findings showed that IRI decreased the proliferation of cancer cells by arresting the cell cycle in the G2/M phase and inducing apoptosis. Similarly, IGFBP-3 had the same effect but induced arrest in the G0/G1 phase. According to the caspase 3/7 activity assay, IRI and combination therapy increased caspase 3/7 activity. Gene expression analysis revealed that IRI decreased Bcl-2 and β-catenin expression while increasing Bax expression. In contrast, IGFBP-3 had no significant effect on these genes. However, the combination therapy produced results similar to IRI alone, albeit slightly stronger. IRI is a prodrug that is activated into its biologically active metabolite, SN-38, through carboxylesterase-mediated hydrolysis(44). Mechanistically, it inhibits DNA topoisomerase I and causes double-strand DNA breaks, resulting in p53-dependent apoptosis. Besides, it can upregulate proapoptotic factors and tumor suppressors such as Bax, p15, and p21(44). Despite its benefits, severe side effects such as neutropenia and diarrhea(45) have limited its clinical use, often leading to low-dose prescriptions for patients. To address this limitation, combination therapies with agents such as cisplatin, curcumin, and 5-FU have been explored(46). IGFBP3 is a well-known member of the IGFBP family. This family consists of proteins produced naturally, and variations in IGFBP-3 have a direct connection with malignancy. Because of this, many studies have been designed to investigate both exogenous and endogenous IGFBP-3. The C-terminal domain of IGFBP-3 plays a crucial role in its function. It facilitates cellular uptake and the production of short 8-22-mer peptide fragments derived from this region. The chemical linkage of these peptides to drugs or nucleic acids helps enhance intracellular delivery and could be useful in therapeutic applications(47). It can inhibit DNA synthesis by binding to IGF and inhibiting IGF-stimulated DNA synthesis(48). Many studies have shown that IGFBP-3 inhibits proliferation and invasion in malignancy by turning off the Akt signaling pathway. Akt inactivation causes the subsequent dephosphorylation of certain targets, notably the activation of glycogen synthase kinase-3 beta (GSK-3β) and inhibition of the mammalian target of rapamycin (mTOR). GSK-3β activation, in particular, may mediate the anti-metastatic effects of IGFBP-3 by promoting β-catenin degradation and inducing differentiation(49). It promotes the degradation of β-catenin through activation of GSK-3β, which leads to the activation of the β-catenin destruction complex associated with the Wnt receptor and the subsequent proteasomal degradation of β-catenin(50). Inhibiting the Wnt/β-catenin pathway can sensitize cancer cells, including colon cancer cells, to drugs. Silencing β-catenin in these cells may decrease drug resistance and enhance sensitivity to IRI(51). Inhibition or inactivation of the Akt pathway by IGFBP3 not only induces apoptosis but also helps prevent resistance mechanisms that cancer cells activate to repair IRI-induced DNA damage. This occurs through increased oxidative stress and elevated ROS levels in the cancer cells, which impair DNA repair processes and sensitize the cells to IRI treatment(5253). Based on studies, it is clear that IGFBP3 induced apoptosis in cancer cells by binding to the nuclear retinoid X receptor α (RXR-α), which is necessary for apoptosis. On the other hand, this process is not only independent of the p53 pathway but also depends on the ratio of proapoptotic to anti-apoptotic proteins, such as the Bax/Bcl-2 ratio(54). Based on its pathway and pro-apoptotic effects, IGFBP3 induces cell cycle arrest at the G2/S phase through interaction with the transforming growth factor-β (TGF-β) receptor and BAX protein(55). In our study, Bax expression was upregulated, while Bcl2 was downregulated in the combination treatment group. Furthermore, genomic analysis of apoptotic cells revealed an increased percentage of cells in the G0 phase in this group. As previously mentioned, separate studies have shown that exogenous IGFBP3 can reduce the proliferation of cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway, which is responsible for proliferation. IRI primarily induces apoptosis by upregulating p53 and Bax and downregulating Bcl-2, causing cell cycle arrest in the G2/M phase. While our study demonstrated the promising synergistic effects of IGFBP-3, its potential side effects warrant consideration. As a natural protein, IGFBP3 is generally well-tolerated in preclinical models. However, its primary mechanism of action, sequestering IGFs and inhibiting IGF-1R signaling, raises theoretical concerns about systemic metabolic consequences, given the crucial role of the IGF axis in normal glucose metabolism and tissue homeostasis. Furthermore, its pro-apoptotic and growth-inhibitory effects, while beneficial in cancer cells, could potentially affect rapidly dividing normal cells. This underscores the importance of our proposed future work using normal cell lines to specifically evaluate the safety profile of IGFBP-3, both alone and in combination with IRI, to fully assess its therapeutic window. CONCLUSION The obtained results of the current study indicated that IGFBP3 and IRI have synergistic effects on SW480 cells, with IGFBP3 amplifying the effects of IRI, including inducing apoptosis, arresting the cell cycle, and increasing cellular ROS. To address the limitation of this study concerning the effect of the treatments of interest on the intact cells and to give more credibility to the obtained results, utilizing a normal cell line to observe the potential adverse effects of IGFBP3, IRI, and their combination is recommended. However, we were unable to include a normal cell line due to limited financial resources and the availability of IGFBP3. Authors’ contributions M. Shekarzadeh and E. Gharekhani designed the study. E. Gharekhani conducted the study, analyzed the data, and wrote the article. M. Shekarzadeh and M. Karami edited and revised the article. A. Bagheri reviewed the data analysis. E. Gharekhani and M. Rahmati Kukandeh drafted the manuscript and edited the article. All authors have read and approved the finalized article. Each author has fulfilled the authorship criteria and affirmed that this article represents honest and original work. Conflict of interest statement The authors declared no conflict of interest in this study. AI declaration During the preparation of this work, the author used Perplexity and Grammarly to improve readability and language, as well as to generate a graphical abstract. After using this tool, the author reviewed and edited the content and takes full responsibility for the content of the publication. Data availability The data supporting the findings of this study are documented and available from the corresponding author upon reasonable request. Researchers interested in accessing the data should contact the corresponding author to discuss the terms and conditions of access.